A股異動 | 湖北宜化(000422.SZ)漲停 擬與寧波邦普在新能源電池材料配套化工原料領域開展合作
格隆匯10月12日丨湖北宜化(000422.SZ)午後漲停,現報21.02元,封單不足一萬手,暫成交25億元,最新市值188億元,換手率達14.73%。湖北宜化今日午間公佈,為推動公司磷化工產業轉型升級,利用公司的資源優勢,發展新能源產業,2021年10月12日,公司與寧波邦普時代新能源有限公司(簡稱“寧波邦普”)在湖北省武漢市簽署了《關於一體化電池材料配套化工原料項目合作意向協議》,就建設一體化電池材料配套化工原料項目達成合作意向協議,擬與寧波邦普在新能源電池材料配套化工原料領域開展合作。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.